Brief: Ligand’S Partner Viking Therapeutics Announces Positive Top-Line Results From Phase 2B Voyage Study

Ligand Pharmaceuticals Incorporated

16/05/2023 12:33

May 16 (Reuters) - Ligand Pharmaceuticals Inc  LGND.O :
    * LIGAND’S PARTNER VIKING THERAPEUTICS ANNOUNCES POSITIVE
TOP-LINE
RESULTS FROM PHASE 2B VOYAGE STUDY OF VK2809 IN PATIENTS WITH
BIOPSY-CONFIRMED NON-ALCOHOLIC STEATOHEPATITIS (NASH)
    * LIGAND PHARMACEUTICALS INC - IS ENTITLED TO RECEIVE A $10
MILLION MILESTONE PAYMENT UPON INITIATION OF A PHASE 3 CLINICAL
TRIAL
    * LIGAND PHARMACEUTICALS INC - LIGAND IS ENTITLED TO RECEIVE
ROYALTIES OF 3.5% TO 7.5% ON COMMERCIAL SALES OF VK2809, IF
APPROVED

Source text for Eikon:  ID:nBwB4T8pa 
Further company coverage:  LGND.O